SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · CRGI stake drops to 8.2%

ALNYLAM PHARMACEUTICALS, INC. · SC 13G/A filed Nov 13, 2026 at 17:08 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 13, 2026 at 17:08 ET

Capital Research Global Investors (CRGI) filed an amended Schedule 13G disclosing a 8.2% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, down from 10.4% in the prior filing. The reduction reflects routine portfolio rebalancing by a large passive holder and does not signal any change in investment intent or control.

  • CRGI disclosed beneficial ownership of 10,940,905 shares of Alnylam common stock as of September 30, 2026.
  • The stake represents 8.2% of the 133,809,118 shares outstanding.
  • This is a decrease from the prior filing where CRGI reported a 10.4% stake.
  • The filing certifies passive intent with no plans to influence control.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access